| Project/Area Number |
25670025
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Biological pharmacy
|
|---|
| Research Institution | Osaka University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
NONOMURA Iwao 大阪大学, 医学系研究科泌尿器科, 教授 (30263263)
UEMURA Motonao 大阪大学, 医学系研究科泌尿器科, 教授 (40631015)
FUJITA Kazutoshi 大阪大学, 医学系研究科泌尿器科, 教授 (50636181)
|
|---|
| Project Period (FY) |
2013-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Keywords | 淡明型腎細胞がん / 患者がん組織移植マウス / LOXL2 / 悪性化 / 幹細胞 / 腎癌 / 癌患者組織移植マウス / 癌幹細胞 / miRNA / 患者癌組織移植マウス / 増殖因子 |
|---|
| Outline of Final Research Achievements |
Clear cell renal cell carcinoma (ccRCC) is the most popular subtype of renal cell carcinoma (RCC). Early-stage ccRCC is curable by clinical surgery, but approximately one-third of all patients present locally metastatic cancer at the time of diagnosis. Therefore, an understanding of the molecular mechanisms of ccRCC progression is crucial for the discovery of molecular-targeted therapies. In the present study, we have established patient-derived xenograft models of ccRCC. The tumors serially transplanted in mice pathohistologically showed high-grade phenotypes. On the other hand, we found LOX-like protein 2 (LOXL2) that is involved in the progression of ccRCC. Our findings suggest that LOXL2 is a potent regulator of integrin α5/β1 protein levels and functions in a tumor-promoting capacity in ccRCC.
|
